Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | SHBG | P04278 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALPG | P10696 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833396 | 0.89 | CTBP2 (0.56) | NPC1RAB9ACTBP2L3MBTL1MAPT | |
| SCHEMBL24403579 | 0.88 | HTT (0.50) | NPC1RAB9ACTBP2L3MBTL1MAPT | |
| SCHEMBL6584846 | 0.87 | CA12 (0.53) | NPC1RAB9ACTBP2ENPP2KDM4E | |
| SCHEMBL22646235 | 0.83 | NPC1 (0.50) | NPC1RAB9AL3MBTL1MAPTDPP4 | |
| SCHEMBL148710 | 0.82 | MAPT (0.69) | NPC1RAB9AL3MBTL1MAPTDPP4 | |
| SCHEMBL4296495 | 0.80 | CTBP2 (0.44) | NPC1RAB9ACTBP2L3MBTL1MAPT | |
| SCHEMBL5727380 | 0.80 | NPC1 (0.55) | NPC1RAB9ACTBP2ESR2 | |
| SCHEMBL1642242 | 0.80 | NPC1 (0.81) | NPC1RAB9AL3MBTL1MAPTSRD5A2 | |
| SCHEMBL10420734 | 0.79 | LOXL2 (0.59) | NPC1RAB9AMAPTKDM4EALDH1A1 | |
| SCHEMBL14855982 | 0.79 | ESR1 (0.72) | NPC1RAB9AMAPTESR1SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501819-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-09-15 | — | — | EP | disclosed |
| EP-1501819-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2010-09-15 | — | — | EP | disclosed |
| US-7138426-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1501819-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050234245-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-10-20 | — | — | US | disclosed |
| EP-1501819-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| US-6750213-B2 | BONE DISORDERS; UROGENITAL SYSTEM DISORDERS; ANTICANCER AGENTS | MERCK & CO., INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030225132-A1 | Heterocyclic salts such as 3-(3-Hydroxyphenyl)-2-(4-(2-(1-pyrrolidinium)ethoxyphenol)-2,3-dihydro-1,4 -benzoxathiin-6-ol hydrochloride salt, used as estrane agonists, for phrophylaxis of bone disorders | DININNO FRANK P (US) | 2003-12-04 | — | — | US | disclosed |
| WO-2003091239-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003086388-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003087073-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20020165226-A1 | Estrogen receptor modulators | MERCK & CO., INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165226-A1 | Estrogen receptor modulators | ESRRA, GPER1, ESRRB | NPC1 945/4885RAB9A 3951/4885CTBP2 4311/4885 |
| US-20050234245-A1 | Estrogen receptor modulators | ESRRB, ESR2, GPER1 | NPC1 887/4885RAB9A 3871/4885CTBP2 3936/4885 |
| US-20030225132-A1 | Heterocyclic salts such as 3-(3-Hydroxyphenyl)-2-(4-(2-(1-pyrrolidinium)ethoxyphenol)-2,3-dihydro-1,4 -benzoxathiin-6-ol hydrochloride salt, used as estrane agonists, for phrophylaxis of bone disorders | GPER1, ESR2, ESR1 | NPC1 840/4885RAB9A 4442/4885CTBP2 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.